defin
chronic
inflammatori
airway
disord
bronchial
hyperrespons
varieti
stimuli
bronchial
asthma
often
punctuat
recurr
episod
exacerb
classic
manifest
wheez
breathless
chest
tight
nocturn
earli
morn
cough
episod
usual
associ
widespread
variabl
airflow
obstruct
within
lung
often
revers
either
spontan
treatment
convent
nebul
shortact
agonist
saba
like
salbutamol
often
use
reliev
acut
exacerb
asthma
howev
recent
worldwid
respiratori
outbreak
pandem
flu
sever
acut
respiratori
syndrom
sar
outbreak
discourag
routin
nebul
appar
associ
airborn
infect
spread
recent
studi
shown
similar
bronchodil
deliv
via
metereddos
inhal
combin
spacer
produc
least
equival
improv
lung
function
dose
deliv
via
nebul
fact
previou
studi
found
mdi
spacer
dose
reach
lung
rang
total
dose
wherea
jet
nebul
deposit
total
dose
nonetheless
despit
effect
deliv
bronchodil
via
meter
dose
rout
nebul
salbutamol
still
much
prefer
conveni
patient
visit
emerg
depart
expect
given
someth
meter
dose
inhal
take
home
formoterol
longact
laba
rapid
onset
bronchodilatori
effect
within
min
inhal
rapid
bronchodilatori
effect
compar
salbutamol
thu
make
suitabl
altern
treatment
acut
asthma
prevent
exerciseinduc
bronchospasm
fact
formoterol
shown
produc
greater
lung
improv
salbutamol
h
administr
one
reason
formoterol
exhibit
rapid
onset
formoterol
act
full
agonist
receptor
compar
salbutamol
act
partial
agonist
furthermor
addit
nonbronchodilatori
benefici
effect
formoterol
includ
effect
reduc
plasma
exud
close
gap
endotheli
cell
stabil
mast
cell
reduc
neutrophil
recruit
thu
reduc
releas
reactiv
oxygen
speci
activ
neutrophil
combin
budesonideformoterol
singl
inhal
astrazeneca
shown
effect
mainten
reliev
antiasthmat
medic
fact
combin
therapi
recent
use
effect
novel
approach
call
mainten
reliev
therapi
smart
approach
smart
approach
basic
mean
use
mainten
therapi
twice
daili
addit
puff
combin
inhal
need
symptom
relief
random
openlabel
studi
conduct
march
august
compar
effect
strength
mcg
per
inhal
nebul
salbutamol
initi
reliev
acut
exacerb
mild
moder
bronchial
asthma
emerg
depart
hospit
univers
sain
malaysia
husm
defin
mild
moder
asthmat
attack
accord
guidelin
outlin
global
initi
asthma
gina
report
global
strategi
asthma
manag
prevent
adult
patient
age
year
old
came
emerg
depart
husm
mild
moder
asthmat
attack
includ
studi
exclud
patient
refer
district
hospit
health
facil
may
given
reliev
treatment
prior
arriv
pregnanc
patient
alreadi
start
laba
medic
well
patient
persist
poor
inhal
techniqu
despit
taught
proper
techniqu
emerg
depart
studi
approv
hospit
ethic
research
committe
patient
consent
particip
studi
random
receiv
either
two
puff
nebul
salbutamol
patient
random
receiv
given
proper
instruct
inhal
techniqu
use
dummi
turbuhal
devic
suppli
astrazeneca
malaysia
initi
object
paramet
obtain
includ
respiratori
rate
oxygen
satur
peak
expiratori
flow
rate
pefr
patient
reassess
min
object
subject
variabl
relat
studi
record
subject
paramet
relat
patient
percept
symptomat
relief
assess
use
visual
analog
scale
va
likert
scale
breathless
va
wide
use
measur
scale
mani
symptom
includ
pain
breathless
specif
point
time
record
two
read
pre
postintervent
scale
spectrum
complet
asymptomat
one
end
sever
asthmat
symptom
ever
experienc
end
studi
adopt
find
previou
studi
chang
cm
defin
minim
clinic
signific
improv
asthma
manag
emerg
depart
likert
scale
reassess
patient
min
give
alloc
treatment
patient
ask
describ
symptom
relief
scale
much
wors
littl
wors
chang
littl
better
much
better
subsequ
manag
initi
treatment
decis
patient
disposit
decid
accord
discret
treat
doctor
base
clinic
improv
patient
concern
patient
need
admiss
admit
accordingli
patient
nebul
salbutamol
deem
fit
discharg
discharg
inhal
budesonid
mcg
per
inhal
astrazeneca
dose
two
inhal
twice
daili
besid
inhal
salbutamol
asneed
basi
day
patient
arm
discharg
two
inhal
mainten
besid
addit
dose
asneed
basi
eight
dose
day
patient
given
appoint
attend
followup
visit
day
assess
symptom
progress
data
analyz
use
statist
packag
social
scienc
statist
softwar
version
categor
analysi
chisquar
fisher
exact
test
use
numer
analysi
depend
independ
student
ttest
use
parametr
data
wilcoxon
sign
rank
test
mannwhitney
test
use
nonparametr
depend
independ
data
respect
block
random
process
use
studi
gener
use
softwar
avail
web
total
patient
enrol
random
receiv
nebul
salbutamol
receiv
tabl
none
patient
requir
admiss
none
requir
addit
dose
reliev
patient
within
arm
use
pair
ttest
pefr
parametr
wilcoxon
sign
rank
test
respiratori
rate
nonparametr
shown
statist
signific
improv
pefr
reduct
respiratori
rate
improv
tachypnea
patient
use
tubuhal
similar
statist
signific
chang
demonstr
nebul
salbutamol
arm
tabl
arguabl
although
statist
signific
chang
studi
may
notic
clinic
yet
subject
assess
regardless
type
intervent
patient
report
littl
better
likert
scale
anoth
report
much
better
respons
patient
report
improv
va
mean
va
cm
cm
nebul
salbutamol
arm
respect
tabl
specif
arm
likert
scale
nine
patient
said
felt
littl
better
anoth
six
patient
said
felt
much
better
similarli
nebul
salbutamol
arm
nine
patient
felt
littl
better
eight
patient
felt
much
better
likert
scale
none
patient
either
arm
report
feel
chang
littl
wors
much
wors
intervent
tabl
incident
patient
respond
either
littl
better
much
better
perform
posthoc
analysi
use
chisquar
test
compar
subject
improv
versu
nebul
salbutamol
found
statist
signific
differ
two
treatment
p
studi
nebul
salbutamol
demonstr
object
subject
clinic
improv
first
min
although
specif
design
show
noninferior
one
drug
anoth
studi
suggest
effect
nebul
salbutamol
use
reliev
emerg
depart
first
min
consist
find
anoth
studi
effect
salbutamol
metereddos
inhal
even
though
stage
prematur
state
whether
use
altern
reliev
acut
asthmat
attack
nonetheless
demonstr
salbutamol
offer
similar
improv
object
subject
assess
differ
two
studi
sever
limit
inher
weak
methodolog
openlabel
nonblind
trial
involv
small
sampl
size
patient
furthermor
studi
patient
comorbid
durat
asthma
risk
factor
smoke
statu
taken
consider
howev
studi
may
pave
way
larger
studi
futur
studi
benefici
effect
beyond
first
min
whether
use
altern
reliev
better
altern
methodolog
would
add
placebo
inhal
patient
nebul
salbutamol
arm
placebo
nebul
eg
salin
arm
way
confound
bia
due
differ
drug
deliveri
system
could
minim
furthermor
one
common
problem
longterm
asthma
care
poor
adher
inhal
corticosteroid
ic
mainten
therapi
result
undertreat
underli
airway
inflamm
often
patient
understand
differ
mainten
reliev
medic
well
import
regular
ic
use
result
mani
patient
tend
overr
shortact
agonist
medic
quick
relief
symptom
expens
omit
ic
therapi
thu
lower
antiinflammatori
protect
increas
propens
develop
sever
potenti
lifethreaten
exacerb
altern
agent
combin
reliev
mainten
medic
could
use
would
simplifi
treatment
provid
conveni
effect
way
deliv
medic
endobronchi
tree
conclus
studi
show
use
reliev
acut
mild
moder
asthmat
attack
demonstr
statist
differ
compar
nebul
salbutamol
first
min
ultim
recent
develop
mani
respiratori
outbreak
hope
find
studi
translat
help
minim
occurr
unnecessari
nebul
use
altern
agent
equal
effect
also
well
accept
patient
author
receiv
dummi
turbuhal
devic
astrazeneca
malaysia
sole
purpos
patient
educ
support
receiv
astrazeneca
malaysia
ksc
involv
initi
concept
studi
design
data
acquisit
statist
analysi
result
interpret
writeup
manuscript
hk
contribut
design
studi
complet
task
data
acquisit
well
statist
analysi
data
interpret
studi
cwh
contribut
initi
concept
design
well
intellectu
content
studi
author
read
approv
final
manuscript
